Opdivo plus chemotherapy improved median OS to 14.4 months versus 11.1 months in patients with PD-L1 CPS ≥5. The 5-year OS rates were 16% for Opdivo plus chemotherapy and 6% for chemotherapy alone in ...
Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial At a minimum ...
A five-year-old girl from Rhode Island is marking a major milestone in her life by completing her final chemo treatment. On Monday, Amelia Bernard rode in style in a limo that was escorted by police ...
Chemotherapy is a powerful treatment used to fight cancer cells. While highly effective, it can also cause side effects as it targets rapidly dividing cells throughout the body. Understanding these ...
KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck’s anti-PD-1 therapy, has been approved by the Japan ...
Hair loss is one of the most common and emotionally challenging side effects of chemotherapy, affecting self-esteem, identity, and social confidence. Known as chemotherapy-induced alopecia (CIA), it ...
The Oncotype DX Breast Recurrence Score® test, which has been used by over 1.5 million patients, indicates the likelihood of your cancer recurring based on the biology of your tumor. 1,2,3,4 It is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback